Home/Filings/4/0000920465-20-000065
4//SEC Filing

Rolke James 4

Accession 0000920465-20-000065

CIK 0000920465other

Filed

May 3, 8:00 PM ET

Accepted

May 4, 4:09 PM ET

Size

7.0 KB

Accession

0000920465-20-000065

Insider Transaction Report

Form 4
Period: 2020-04-30
Rolke James
Chief Scientific Officer
Transactions
  • Award

    Stock Option (Right to Buy)

    2020-04-30+133133 total
    Exercise: $7.26Exp: 2030-04-30Common Stock (133 underlying)
  • Award

    Common Stock

    2020-04-30$6.17/sh+133$82181,426 total
Footnotes (2)
  • [F1]These shares were acquired on 04/30/2020 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
  • [F2]The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years.

Issuer

LA JOLLA PHARMACEUTICAL CO

CIK 0000920465

Entity typeother

Related Parties

1
  • filerCIK 0001693858

Filing Metadata

Form type
4
Filed
May 3, 8:00 PM ET
Accepted
May 4, 4:09 PM ET
Size
7.0 KB